Drug Development & Delivery: CellProthera Announces Positive Phase 1/2b Data for ProtheraCytes Cell Therapy in Acute Myocardial Infarction

CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following a severe heart attack, positioning the stem cell therapy as a promising option to repair and regenerate heart tissue. The data was presented today by Faiez Zannad, MD, PhD, Chairman of the study’s steering committee and emeritus professor of therapeutics at the Université of Lorraine. Drug Development & Delivery | 17 May 2024 Read on line CellProthera and Alfresa Holdings sign a Memorandum of Understanding to Advance Phase 3 Development and Future wholesale distribution of ProtheraCytes® in Japan 11 August, 2026 Technology Networks: Could Regenerative Medicine Reverse Damage After a Heart Attack? 02 July, 2026 CellProthera Prepares For Phase 3 Push As Regenerative Cardiology Moves Closer To Clinical Reality 02 June, 2026

The release as fetched from its publisher. cellprothera.com ↗